Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2022.04.17.22273938: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Following written informed consent, participants answered a demographic and health history questionnaire. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Plates were washed three times with 0.1% PBST followed by addition of a 1:3,000 dilution of goat anti-human IgG–horseradish peroxidase (HRP) conjugated secondary antibody (50μl) well and incubated 1h. anti-human IgG–horseradishsuggested: NoneGenscript cPass™ surrogate neutralization antibody assay: This semi-quantitative SARS-CoV-2 surrogate neutralizing antibody assay, which measures the inhibition of RBD and ACE2 … SciScore for 10.1101/2022.04.17.22273938: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Following written informed consent, participants answered a demographic and health history questionnaire. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Plates were washed three times with 0.1% PBST followed by addition of a 1:3,000 dilution of goat anti-human IgG–horseradish peroxidase (HRP) conjugated secondary antibody (50μl) well and incubated 1h. anti-human IgG–horseradishsuggested: NoneGenscript cPass™ surrogate neutralization antibody assay: This semi-quantitative SARS-CoV-2 surrogate neutralizing antibody assay, which measures the inhibition of RBD and ACE2 interactions, was performed in accordance with manufacturer’s instructions. ACE2suggested: NoneThis assay is calibrated to the 1st WHO International Standard Anti-SARS-CoV02 Immunoglobulin (Human), NIBSC [26] with results reported in the WHO standard units of IgG Binding Antibody Units/ml (BAU/ml) to recombinant spike S1 domain. Anti-SARS-CoV02suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This work has several limitations, principally the small sample size and variable immune experience of the cohort. Further, as is the case for the majority of the available antibody assays, the Mount Sinai Laboratory assay and the cPass assay have not yet been calibrated to the WHO standard. Our study does provide evidence for a correlation between the Mount Sinai Laboratory and Ortho-Clinical VITROS assays, however. We believe that further standardization of the serological assays to an international standard will allow better correlations of immunity between independent clinical trials. Finally, this study examined only samples immediately prior to breakthrough infection so factors regarding temporal relationship of infection, clinical presentation, and sample collection may have affected our observations. Additional studies including individuals who appear to be susceptible to re-infection or who are poor immunologic responders to SARS-CoV-2 infection and/or vaccination, are needed to better understand differential immune kinetics in those populations. Of particular interest will be characterizing the T-cell immune responses to SARS-CoV-2 in individuals who have developed strong antibody responses yet experience breakthrough infection. Importantly, since we did not compare the titers of breakthrough cases with titers of non-breakthrough cases, we cannot draw conclusions regarding where these titers would fall and if they trend lower than those of individuals who may have b...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
